MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Gastroenterology

Epigenetic Silencing of Hepatocyte FoxO1: A Novel Mechanism Disrupting Liver Immune Balance and Driving Inflammation

MedXY Editorial Team•Aug 18, 2026•Gastroenterology
FoxO1ImmunoregulationNKT cellsLiver inflammationEpigenetics

Highlight

  • Hepatocyte FoxO1 expression is epigenetically repressed via JMJD1C-regulated histone H3K9 dimethylation during liver inflammation.
  • Loss of FoxO1 in hepatocytes disrupts local immune homeostasis by altering NKT cell apoptosis and promoting neutrophil accumulation.
  • FoxO1 induces hepatocyte CD1d expression through retinoic acid synthesis, a critical pathway for controlling NKT cells.
  • Targeting the FoxO1-JMJD1C-CD1d axis offers a novel therapeutic avenue for inflammatory liver diseases such as alcoholic hepatitis and hepatic schistosomiasis.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Palmitic Acid and Cardiac Hypertrophy: Unveiling the Epigenetic Memory Driving Heart FailureThis article explores how palmitic acid induces a pro-hypertrophic memory in cardiomyocytes through epigenetic regulation involving KDM5A and H3K4me3 modifications, driving cardiac hypertrophy and heart failure, and highlights potential theOct 16, 2026Unraveling Abdominal Aortic Aneurysm: Epigenetic Links to Inflammation and Lipid MetabolismAn epigenome-wide study reveals that DNA methylation markers linked to inflammatory pathways and blood lipid traits play a causal role in abdominal aortic aneurysm development, offering potential for improved risk prediction and therapeuticOct 4, 2026Targeting NSD2 Degradation: A Novel Therapeutic Avenue for High-Risk t(4;14) Multiple MyelomaThis article explores the discovery of NSD2-ligand-directed degrader (NSD2-LDD), a promising targeted therapy that degrades oncogenic NSD2 in t(4;14) multiple myeloma, reversing malignant epigenomic programs and improving disease outcomes iSep 30, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
HBV-Induced Immunosuppressive Macrophages: Metabolic and Epigenetic Pathways Driving Chronic Hepatitis B Persistence
This article reviews recent evidence on how HBV manipulates monocyte-to-macrophage differentiation through metabolic and epigenetic reprogramming, facilitating immunosuppression and chronic infection.
Sep 21, 2026
Unveiling PUS7’s Role in Pulmonary Hypertension: A Novel Epigenetic Driver of Vascular RemodelingThis article explores how PUS7-induced pseudouridylation of TGFBI mRNA promotes pulmonary hypertension via epigenetic regulation, revealing promising new therapeutic targets.Sep 4, 2026
Enhancing Prognostic Accuracy in Acute Myeloid Leukemia through DNA Methylation SignaturesDNA methylation profiling in AML patients reveals epigenetic subtypes that mirror genetic mutations, improving risk stratification and outcome prediction beyond standard genetic markers.Aug 28, 2026